Abstract
You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Peyronie's Disease1 Apr 2015PD48-07 CHANGES IN THE EFFECTS OF PEYRONIE'S DISEASE AFTER TREATMENT WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ACCORDING TO MEN WITH PEYRONIE'S DISEASE AND THEIR FEMALE SEXUAL PARTNERS Irwin Goldstein, Dean Knoll, Larry I. Lipshultz, James P. Tursi, Ted M. Smith, Gregory J. Kaufman, Kimberly Gilbert, Raymond C. Rosen, and Chris G. McMahon Irwin GoldsteinIrwin Goldstein More articles by this author , Dean KnollDean Knoll More articles by this author , Larry I. LipshultzLarry I. Lipshultz More articles by this author , James P. TursiJames P. Tursi More articles by this author , Ted M. SmithTed M. Smith More articles by this author , Gregory J. KaufmanGregory J. Kaufman More articles by this author , Kimberly GilbertKimberly Gilbert More articles by this author , Raymond C. RosenRaymond C. Rosen More articles by this author , and Chris G. McMahonChris G. McMahon More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2764AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Collagenase clostridium histolyticum (CCH) is approved as intralesional therapy for treatment of adult men with PD with a palpable plaque and curvature deformity of ≥30 degrees at the start of therapy, and has demonstrated efficacy for the treatment of PD in the double blind, placebo-controlled studies IMPRESS I/II. This study evaluates the effects of CCH treatment in men with Peyronie's disease (PD), their PD symptoms, and female bother reported by the men's female sexual partners (FSPs). METHODS Men with PD who had previously received placebo in IMPRESS I/II received up to 8 injections of CCH 0.58 mg/injection over 24 weeks in this phase 3, open-label study. Assessments included penile curvature deformity measures and the PD questionnaire (PDQ). FSPs who chose to participate in the study completed the female sexual function index (FSFI) and the PDQ for FSPs (PDQ-FSP), a 12-item, investigational questionnaire adapted from the men's PDQ. RESULTS A total of 189 men were enrolled in the study. From baseline to Week 52, a 36.3% (95% CI 30.9%, 41.6%) improvement in penile curvature deformity and a 2.4 point (95% CI 1.8, 3.0) improvement in PDQ bother score was observed in the male subjects. The most common AEs reported were penile hematoma, penile pain, and penile swelling; no serious treatment-related AEs were reported. A total of 30 FSPs participated in the study. Following CCH treatment of their male partners with PD, FSPs reported improvement (using the PDQ-FSP) in both their male partner's PD symptoms and female bother by their partner's PD (mean score reductions of 4.8 and 2.0, respectively). Improvement was also observed on the FSFI scales of desire, arousal, lubrication, orgasm, satisfaction, and pain, as well as the full scale total scores. The proportion of FSPs who reported sexual dysfunction (FSFI total score of <26.55) decreased from 75% at baseline to 33.3% after partner treatment. CONCLUSIONS The efficacy of CCH for the treatment of men with PD observed in this study was consistent with results of previous studies. Exploratory analyses of FSP responses demonstrated decreases in FSP assessments of their partner's PD symptoms as well as female bother by their partner's PD symptoms after their partner's CCH treatment. Improvement in female sexual function was observed as measured by all 6 domains of the FSFI score, and FSP sexual dysfunction decreased. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e968-e969 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Irwin Goldstein More articles by this author Dean Knoll More articles by this author Larry I. Lipshultz More articles by this author James P. Tursi More articles by this author Ted M. Smith More articles by this author Gregory J. Kaufman More articles by this author Kimberly Gilbert More articles by this author Raymond C. Rosen More articles by this author Chris G. McMahon More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.